ReShape Lifesciences Inc.
RSLS
$0.365
-$0.015-3.95%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -8.93% | 6.36% | -12.82% | -15.00% | -36.27% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.93% | 6.36% | -12.82% | -15.00% | -36.27% |
| Cost of Revenue | 247.14% | -1.61% | -21.60% | -26.72% | -90.73% |
| Gross Profit | -28.39% | 11.72% | -5.03% | -4.82% | 15.13% |
| SG&A Expenses | -51.97% | -27.23% | -39.66% | -54.84% | -52.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.88% | -22.92% | -35.83% | -47.54% | -53.52% |
| Operating Income | 66.12% | 43.25% | 48.77% | 60.75% | 63.78% |
| Income Before Tax | -5.34% | 55.40% | 54.71% | 17.71% | 89.91% |
| Income Tax Expenses | -83.87% | 100.00% | 275.00% | 0.00% | 155.36% |
| Earnings from Continuing Operations | -3.71% | 55.26% | 54.34% | 17.62% | 89.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.71% | 55.26% | 54.34% | 17.62% | 89.69% |
| EBIT | 66.12% | 43.25% | 48.77% | 60.75% | 63.78% |
| EBITDA | 66.26% | 42.48% | 48.28% | 60.52% | 59.97% |
| EPS Basic | 61.41% | 94.77% | 94.12% | 94.00% | -- |
| Normalized Basic EPS | 61.61% | 93.31% | 92.65% | 94.01% | -- |
| EPS Diluted | 61.41% | 94.77% | 94.12% | 94.00% | -- |
| Normalized Diluted EPS | 61.61% | 93.31% | 92.65% | 94.01% | -- |
| Average Basic Shares Outstanding | 168.70% | 755.29% | 676.61% | 1,270.85% | -- |
| Average Diluted Shares Outstanding | 168.70% | 755.29% | 676.61% | 1,270.85% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |